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Background: The study aims to associate serum insulin-like growth factor-1 (IGF-1) levels with cervical maturation
stages (CS) 3, 4, and 5 on lateral cephalogram in male subjects and to find out peak serum IGF-1 levels among
these three stages.
Methods: The study was conducted on 45 male subjects who were at skeletal maturation stage CS-3, CS-4, and
CS-5. Subjects were selected using simple random sampling technique. Serum IGF-1 levels were estimated from
blood samples using chemiluminescence immunoassay (CLIA) method. CS was evaluated using a six-stage method
of evaluating the cervical vertebrae. Mean IGF-1 levels between the stages were compared by analysis of variance
(ANOVA) test.
Results: One-way ANOVA showed highly significant differences between all cervical stages with p value <0.01, but
post hoc Tukey test showed highly significant differences between CS-4 and CS-5 with p value 0.006. Serum IGF-1
levels showed good association with skeletal age in male subjects; 53.3% of subjects at CS-3, 66.7% subjects at CS-4,
and 6.7% subjects at CS-5 showed IGF-1 levels in peak range.
Conclusions: Serum IGF levels can be used as an additional tool to optimize orthodontic treatment timing.Background
The assessment of growth potential is essential because
of individual variations in timing, duration, and velocity
of growth. The classic method of assessing skeletal ma-
turity is by the use of a hand-wrist radiograph. Assessing
the degree of cervical vertebral maturation on lateral
cephalometric radiograph [1-8] and recording MP3 sta-
ges [9,10] on periapical X-ray films are also used to iden-
tify peak mandibular bone growth and skeletal maturity.
Radiographic methods, which are highly subjective tech-
niques, involve radiation exposure. More recently, the
use of some additional methods with cervical maturation
method for the assessment of biologic maturity is pro-
posed [11,12]. If the shape of the cervical vertebrae does
not show the exact stage, then additional method can be
of use to predict the maturation stage accurately.
Gingival crevicular fluid alkaline phosphatase level
may be used as a noninvasive clinical biomarker for the
identification of pubertal growth spurt but only in* Correspondence: sapnajainorthogdcindore@gmail.com
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in any medium, provided the original work is pperiodontally healthy subjects [13]. Insulin-like growth
factor-1 (IGF-1) is one of the main mediators of the ac-
tions of growth hormone in promoting muscular and
skeletal growth [14-16]. Parallel to the increase in
growth hormone secretion at puberty, circulating IGF-1
also increases [17]. A study has shown that the condyle
is more responsive and sensitive to IGF-1 than the fem-
oral head [18]. Mean IGF-1 blood spot levels in the late
pubertal stages have been observed to be higher than in
the prepubertal, early pubertal, and postpubertal stages
[19]. IGF-1 levels were highest at the hand-wrist stages
that are previously associated with the greatest amount
of mandibular growth [20].
Reference ranges of serum IGF-1 levels in male and fe-
male subjects have been established separately according
to chronological age [21]. Age-related increase occurs in
serum IGF-1 levels during the prepubertal and early
pubertal stages and a decrease in late puberty, but
chronological age is not a reliable indicator for skeletal
maturity [22-24].
Since IGF-1 levels vary according to age and sex [21],
separate studies are needed for male and female subjects.
The pubertal peak occurs approximately 2 years earlieropen access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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maturation factor for the assessment of skeletal maturity
[26]. Since serum IGF-1 quantitatively assesses growth,
the intensity of growth can therefore be estimated which
would further help in assessing the exact timing of
treatment.
The purpose of this study was to associate serum IGF-
1 levels with cervical vertebrae maturation stages so as
to find out whether IGF-1 levels can be used as a clinical
tool or not. The objective was to find out peak serum
IGF-1 levels corresponding to cervical vertebrae ma-
turation stages (CS) 3, 4, and 5 in circumpubertal male
subjects.Methods
The sample used in the study consisted of 45 male sub-
jects, who were at CS-3, CS-4, and CS-5, selected from
the patients coming to the Department of Orthodontics
and Dentofacial Orthopedics and Department of Pedo-
dontics at our institute by simple random technique. Pa-
tients meeting the set selection criteria were selected
from the daily patient register until a sample size of 15
was reached in each group to eliminate both deliberate
and unconscious bias. Inclusion criteria were male sub-
jects who were at CS-3, CS-4, and CS-5 based on infor-
mation about birth date and their good health status.
Exclusion criteria were subjects suffering from any ser-
ious illness; growth abnormality, e.g., craniofacial syn-
dromes, rickets, medical syndromes, bone disease, and
bone deformities; bleeding disorders, or history of any
serious trauma or injury to the face. The research pro-
tocol was approved by the ethical committee of the
Government College of Dentistry, Indore, India. Parental/
patient's informed consent was taken for enrolment of
each subject in the study.
Lateral cephalograms were taken in natural head po-
sition within an hour of blood collection. All the radio-
graphs were exposed at 80 kVp, 9 mA for 1.25 s. The
six-stage cervical staging technique by Baccetti et al. [6]
was used to determine the stages of cervical vertebrae
maturation. The observer was blinded about each pa-
tient's age and IGF-1 levels. A double determination was
carried out on all the 45 individual's radiographs by the
same operator at a second session after 15 days. TheseTable 1 Descriptive IGF-1 (ng/ml) statistics for each cervical s
Cervical stage Subjects Mean IGF-1 (ng/ml) SD
CS-3 15 318 17.4
CS-4 15 352 17.7
CS-5 15 279 10.8
ANOVA: p value = 0.008, highly significant. SD, standard deviation.tracings were analyzed separately, and two sets of rea-
dings were obtained for statistical evaluation.
Blood samples were collected between OPD hours of
9:00 a.m. and 12:00 p.m., and serum was separated from
the blood samples, labelled with patient's name, properly
sealed, stored in a thermocol box with ice pack (kept at
2°C to 8°C), and sent to the laboratory for chemilumin-
escence immunoassay for determination of IGF-1 levels
by a fully automated, two-site chemiluminescent immu-
noassay (Siemens Immunolite 2000 (Siemens, Munich,
Germany) immunoassay machine at Metropolis Labora-
tories). Each patient's height and weight were measured
as they might affect serum IGF-1 levels.
Statistical analysis
The Pearson correlation was used to measure intra-
examiner reliability. The mean Pearson correlation for
all variable was 0.932, and it ranged from 0.801 to 0.988,
which implies a highly significant correlation between
the observations (p = <0.01).
Analysis of variance (ANOVA) and post hoc tests were
used to compare mean IGF-1 levels and cervical verte-
bral maturation stages. All statistical analyses were per-
formed using SPSS18 for Windows software (version
18.0; SPSS, Chicago, IL, USA). The significance level was
set at p < 0.01. Student's t test was applied to show signifi-
cant differences between the orthodontic classes (CS-5)
and orthopedic groups (CS-3 and CS-4).
Results
Differences were observed between the cervical stages
(p < 0.01) when analyzed by one-way ANOVA (Table 1);
highly significant differences were found between CS-4
and CS-5 (p = 0.006), whereas nonsignificant differences
were found between CS-3 and CS-4, and between CS-3
and CS-5 by post hoc Tukey test (Table 2).
Peak IGF-1 level was found in CS-4. In the CS-5
group, IGF-1 level was consistently on the lower hub in
all three maturity groups, suggesting the fact that most
patients attain their maximum growth by the time of
CS-5 (Table 3).
Table 4 shows the mean IGF-1 level with respect to
orthodontic and orthopedic groups. By Student's t test,
highly significant differences were observed between the
classes and serum IGF-1 level with a p value of 0.006.tage
95% confidence interval for mean Minimum Maximum
Lower bound Upper bound
283 353 171 433
317 387 252 525
257 301 206 372
Table 2 Post hoc analysis (least significant difference
comparing IGF-1 serum levels (ng/ml)) for CS-3, CS-4,
and CS-5
Group (mean) Compared group Mean difference SE p value
CS-3 (318.13) CS-4 (352.40) −34.27 22.05 0.277
NS
CS-4 (352.40) CS-5 (279.67) 72.73 22.05 0.006
Sig
CS-5 (279.67) CS-3 (318.13) −38.47 22.05 0.201
NS
NS, nonsignificant (p > 0.05); Sig, significant (p < 0.05); SE, standard error.
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increased with increasing age at CS-3 and decreased
with age at CS-4 and CS-5. Serum IGF-1 level increased
up to 15 years of age and decreased thereafter.
Discussion
The present study was done to evaluate serum IGF-1
levels in CS-3, CS-4, and CS-5 (circumpubertal growth
period) because these stages are clinically more relevant
stages with the orthodontic speciality. The cervical sta-
ging determination method used which was given by
Baccetti et al. [6] is considered to be a better method in
comparison to other methods [27].
In the present study, mean peak serum IGF-1 level in
male subjects at CS-4 (352 ng/ml) was observed, in con-
trast to a similar study where mean peak IGF-1 level at
CS-3 (397 ng/ml) was noticed in female subjects [28]. A
possible explanation for the difference observed in stages
where peak in IGF-1 levels between the two studies is
observed could be related to gender difference since the
timing of puberty differs in male and female subjects [1].
This is in accordance with the statement by Proffit [29]:
“Girls mature earlier, and finish their growth much
sooner. The differences arise because in males slow but
steady growth occurs before the growth spurt.” It was
also observed that 53.3% (8 out of 15) of the subjects at
CS-3, 66.7% of the subjects (10 out of 15) at CS-4, and
6.7% of the subjects (1 out of 15) at CS-5 showed IGF-1
levels in peak range.
The scatter curve showed that serum IGF-1 levels
increased with age in CS-3 and decreased with age in
CS-4 and CS-5, which means that the peak in serum
IGF-1 may occur at the fag end of CS-3 and at the be-
ginning of CS-4. The observed peak IGF-1 levels at CS-3
and CS-4 in the present study coincide with cervical
stages with peak mandibular growth, observed by Bac-
cetti et al. [6] in 2005.
The mean serum IGF-1 level in the CS-4 group is
352 ± 17.7 ng/ml with a mean age of 15.9 years, which isin accordance with the study by Brabant et al. [21], in
which the highest mean IGF-1 was 382 ng/ml for males
which occurred at the age of 15 to 16 years. Studies
[21,25] have attempted to establish a reference range of
serum IGF-1 levels according to chronological age in
male and female subjects separately, but several studies
have shown that chronological age is a poor predictor of
the pubertal growth spurt [22-24].
The present study showed the range of serum IGF-1
levels as 171 to 433 ng/ml for CS-3, 252 to 525 ng/ml
for CS-4, and 206 to 372 ng/ml for CS-5. The clinical
usefulness of the study is limited because of overlapping
levels of serum IGF-1 in all three cervical stages, possibly
due to the relatively small sample size, cross-sectional de-
sign of the study, different body types (aesthetic/athletic/
plethoric), and different maturational groups (advanced/
average/delayed).
In order to use IGF-1 levels as a diagnostic tool in
clinical orthopedic case selection and for establishing a
cutoff reference value of IGF-1 for different types of
treatments, the subjects in CS-3, CS-4, and CS-5 were
divided into two groups. Since post hoc analysis revealed
no statistical difference in CS-3 and CS-4, therefore, the
subjects at CS-3 and CS-4 were combined and con-
sidered as class 1 (orthopedic treatment type) in which
orthopedic corrections are possible, and subjects at CS-5
were considered as class-2 (orthodontic treatment type).
After statistical analysis of these two treatment classes,
new upper and lower bound limits of IGF-1 levels were
obtained which were 310 and 360 ng/ml, respectively,
for orthopedic treatment class and 258 and 302 ng/ml
for orthodontic treatment class. Based on these upper
and lower bound values, a cutoff value of serum IGF-1
levels for various treatment options was obtained as
310 ng/ml. This means that in patients with serum
IGF-1 levels >310 ng/ml, orthopedic treatment may be
considered.
To gain additional information about maturational
status of growth, the sample was further divided into
three groups (advance, average, and delayed maturer)
in each cervical stage on the basis of lower and upper
bound limits of age. Samples below the lower bound
limit of age were considered as advance maturers,
those within the lower and upper bound limit of age
were average maturers, whereas those above the
upper bound limit of age were considered as delayed
maturers.
In CS-3, much higher IGF-1 levels were found in de-
layed maturers (subjects above the upper bound limit of
age). This finding can be useful in clinical orthodontic
practice as in delayed type of maturers at CS-3 treat-
ment should be started without delay. In delayed ma-
turers at CS-3, mean height and weight also increased,
which was possibly the explanation for increased IGF-1




























CS-3 13.4 13.2 13.7 317 61.9 40.2 288 61.3 39.8 339 61.6 42.1
(226–372) (59–64) (36–43) (171–369) (58–62) (38–42) (253–389) (59–65) (39–46)
(<13.2 years) (13.2–13.7 years) (>13.7 years)
CS-4 15.9 15.6 16.2 381 65.2 42.4 318 65.2 42.8 352 66.3 48.2
(300–525) (62–68) (38–46) (252–398) (58–71) (37–52) (275–427) (64–68) (42–50)
(<15.6 years) (15.6–16.2 years) (>16.2 years)
CS-5 17.3 17.0 17.5 293 67.6 51.1 278 68.0 57.1 267 67.5 52.6
(222–372) (66–68) (45–56.5) (206–311) (65–70) (52–64) (241–304) (67–68) (48–60)
(<17.0 years) (17.0–17.5 years) (>17.5 years)
Advance maturers, subjects with age less than the lower bound age limit in each cervical stage. Average maturers, subjects with age within the upper and lower bound age limit in each cervical stage. Delayed

















Table 4 Mean IGF-1 level (ng/ml) with respect to orthopedic and orthodontic treatment class
Group Subjects Mean IGF-1 (ng/ml) SD Median 95% confidence interval for mean p value
Lower bound Upper bound
Class 1 30 335 12.6 333 310 360 0.006
Class 2 15 280 10.8 285 258 302
SD, standard deviation; Class 1, orthopedic treatment class; Class 2, orthodontic treatment class.
Jain et al. Progress in Orthodontics 2013, 14:46 Page 5 of 7
http://www.progressinorthodontics.com/content/14/1/46levels in this group. The serum IGF-1 level was consis-
tently on the lower hub in CS-5 in all three maturity
groups, suggesting the fact that most patients attain
their maximum growth by the time of CS-5. However,
IGF-1 levels of early maturers were relatively higher than
average and those of delayed type of maturers.
Another study [26] established mean serum IGF-1
levels for both sexes in all CVMI stages which were
higher compared to those in our study; however, their
method involved ELISA, a different technique to mea-
sure serum IGF-1 levels. The difference in meanIGF-1 levels at CS-3 (blue) 
IGF-1 levels at CS-4 (green) 
IGF-1 levels at CS-5 (yellow) 
Mean IGF-1 levels at different ages  
Figure 1 Scatter curve showing change in IGF-1 levels with age withiserum IGF-1 levels may also be due to different study
populations.
According to Ball et al. [11], on average, patients re-
main in CS-3 for 1.77 years and in CS-4 for 3.79 years.
Often, we do not know at what time of the stage the
cephalogram was taken, thus making it very difficult to
assess the exact timing of growth spurt. The cervical ver-
tebral maturation stages should be used along with other
methods of biologic maturity assessment when considering
both dentofacial orthopedic treatment and orthognathic
surgery. The following combined classification may beCS-3: R2 Linear = 0.123(0.046)
CS-4: R2 Linear = 0.010
CS-5: R2 Linear = 0.107
n the same cervical stage.
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ment groups:
Group 1: cervical stages 3 and 4 with IGF-1 levels less
than 310 ng/ml.
Group 2: cervical stages 3, 4, and 5 with IGF-1 levels
more than 310 ng/ml.
Group 3: cervical stage 5 with IGF-1 levels less than
310 ng/ml.
Different clinical studies on the skeletal response of
functional appliance have shown different treatment re-
sults; this may be due to the different designs of appli-
ance, duration of treatment, patient's cooperation, type
of malocclusion, and also on different maturational sta-
tuses as well as type of maturers. Hence, to reduce over-
all treatment timing, it would be better to follow new
combined group criteria on the basis of cervical staging
and quantitative assessment of IGF-1 levels. A patient
showing CS-3 with serum IGF-1 levels less than 310 ng/ml
can wait for IGF-1 level reevaluation to start treatment
with functional appliance.
If a patient is at cervical stage 3, 4, or even 5 and has a
serum IGF-1 level more than 310 ng/ml, treatment for
functional jaw orthopedics can be chosen. If IGF-1 level
is >310 ng/ml and cervical stage is 5, orthopedic treat-
ment may be started without delay because very little
time for growth is remaining. Since IGF-1 levels vary as
per body type (athletic, aesthetic, and plethoric) and type
of maturers (early, average, and late), longitudinal study
with larger sample size consisting of similar body type
and type of maturer might result in establishing a clini-
cally useful reference range.Conclusions
Serum IGF-1 levels may be used as an additional tool for
optimizing orthodontic treatment timing. Further studies
with larger sample size are required to prove this.
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